Table of Contents
1 Table of Contents 2
1.1 List of Tables 10
1.2 List of Figures 13
2 Introduction 15
2.1 What Is This Report About? 15
3 Definitions of
Markets Covered in This Report 16
4 In Vitro Diagnostics 16
4.1
Clinical Chemistry Test Reagents 16
4.1.1 Laboratory Reagents 16
4.1.2
Clinical Chemistry Calibrators and Controls 16
4.1.3 Clinical Chemistry
Rapid Tests 16
4.2 Immunochemistry Test Reagents 16
4.2.1 Disease
Specific Markers 16
4.2.1.1 Tumor Markers 16
4.2.1.2 Cardiac Markers
17
4.2.2 Disease Specific Test Reagents 17
4.2.2.1 Auto-Immune Disease
17
4.2.2.2 Rheumatoid Disease 17
4.2.2.3 Anemia/ Vitamins 17
4.2.2.4 Allergy 17
4.2.3 Drug Related Testing Reagents 17
4.2.3.1
Therapeutic Drugs 17
4.2.3.2 Drug of Abuse and Toxicology 18
4.2.4
Hormone Related Testing Reagents 18
4.2.4.1 Specific Proteins 18
4.2.4.2 Fertility and Pregnancy 18
4.2.4.3 Individual/Specified hormones
18
4.2.4.4 Specific Organ Function 18
4.2.5 Immunochemistry
Calibrators and Controls 18
4.2.6 Immunochemistry Rapid Tests 18
4.3
Blood Test Reagents 18
4.3.1 Hematology Test Reagents 18
4.3.1.1
Hematology 19
4.3.1.2 Immunohaematology 19
4.3.1.3 Hematology
Calibrators and Controls 19
4.3.1.4 Immunohaematology Controls 19
4.3.2 Hemostasis Test Reagents 19
4.3.2.1 Hemostasis 19
4.3.2.2
Hemostasis Calibrators and Controls 19
4.3.2.3 Hemostasis Rapid Tests
19
4.3.3 Tissue Typing Reagents 19
4.3.4 Monoclonal Antibodies 20
4.3.5 Cytokines and Immunomodulators 20
4.3.6 Histology and Cytology
Reagents 20
4.4 Microbiology Test Reagents 20
4.4.1 Bacteriology Test
Reagents 20
4.4.1.1 Bacteriology Culture 20
4.4.1.2 Blood Culture
20
4.4.1.3 Bacteriology Identification and Susceptibility 20
4.4.2
Microbiology Calibrators and Controls 20
4.4.3 Microbiology Rapid Tests
21
4.5 Infectious Immunology Test Reagents 21
4.5.1 Bacteriology
21
4.5.2 Virology 21
4.5.2.1 Hepatitis Viruses 21
4.5.2.2
Retroviruses 21
4.5.3 Parasitology 21
4.5.4 Infectious Immunology
Calibrators and Controls 21
4.5.5 Infectious Immunology Rapid Tests 21
4.6 Genetic Test Reagents 21
4.7 Self Testing 22
4.8 Instruments
22
5 Healthcare Sector Review 23
5.1 Healthcare Expenditure 23
5.2
Healthcare Infrastructure 24
5.2.1 Healthcare Personnel Data 25
5.2.2
Healthcare Facilities Data 26
5.3 Healthcare Policy 29
6 Regulation
System 30
6.1 Medical Equipment Approval Process 30
6.1.1
Classification 30
6.1.2 Registration and Conformity assessment 31
6.1.3 China Compulsory Certificate (CCC Mark) 33
6.1.4 Labeling and
Packaging 34
6.1.5 Registration Fee 35
6.1.6 Registration Period
35
6.2 Post Market Surveillance (PMS) 35
7 Pricing and Reimbursement
36
8 Distribution Structure 38
9 In Vitro Diagnostics In China 39
9.1 In Vitro Diagnostics Cross Country Comparison, Revenue ($ mn), 2000-2015
39
9.2 In Vitro Diagnostics, China, Overall Revenue ($ mn), 2000-2015
40
9.3 In Vitro Diagnostics, China, Company Share (2006-2007) 46
10
Blood Test Reagents In China 47
10.1 Blood Test Reagents Overall Revenue
(2000-2015) 47
10.1.1 Haematology Test Reagents Revenue (2000-2015) 51
10.1.2 Hemostasis Test Reagents Revenue (2000-2015) 53
10.2 Blood Test
Reagents Distribution Share (2007-2008) 55
10.3 Blood Test Reagents,
China, Company Share (2006-2007) 56
11 Clinical Chemistry Test Reagents In
China 57
11.1 Clinical Chemistry Test Reagents Overall Revenue (2000-2015)
57
11.2 Clinical Chemistry Test Reagents Distribution Share (2007-2008)
59
11.3 Clinical Chemistry Test Reagents, China, Company Share (2006-2007)
60
12 Genetic Test Reagents In China 61
12.1 Genetic Test Reagents
Overall Revenue (2000-2015) 61
12.2 Genetic Test Reagents Distribution
Share (2007-2008) 63
12.3 Genetic Test Reagents, China, Company Share
(2006-2007) 64
13 Immunochemistry Test Reagents In China 65
13.1
Immunochemistry Test Reagents Overall Revenue (2000-2015) 65
13.1.1
Disease Specific Markers Revenue (2000-2015) 69
13.1.2 Disease Specific
Test Reagents Revenue (2000-2015) 71
13.1.3 Drug Related Testing Reagents
Revenue (2000-2015) 73
13.1.4 Hormone Related Testing Reagents Revenue
(2000-2015) 75
13.2 Immunochemistry Test Reagents Distribution Share
(2007-2008) 77
13.3 Immunochemistry Test Reagents, China, Company Share
(2006-2007) 78
14 Infectious Immunology Test Reagents In China 79
14.1
Infectious Immunology Test Reagents Overall Revenue (2000-2015) 79
14.1.1
Virology Revenue (2000-2015) 83
14.2 Infectious Immunology Test Reagents
Distribution Share (2007-2008) 85
14.3 Infectious Immunology Test
Reagents, China, Company Share (2006-2007) 86
15 Instruments In China
87
15.1 Instruments Overall Revenue (2000-2015) 87
15.2 Instruments
Distribution Share (2007-2008) 89
Instruments, China, Company Share
(2006-2007) 90
Instruments, China, Company Share (2006-2007) 90
16
Microbiology Test Reagents In China 91
16.1 Microbiology Test Reagents
Overall Revenue (2000-2015) 91
16.1.1 Bacteriology Test Reagents Revenue
(2000-2015) 93
16.2 Microbiology Test Reagents Distribution Share
(2007-2008) 95
16.3 Microbiology Test Reagents, China, Company Share
(2006-2007) 96
17 Self Testing In China 97
17.1 Self Testing Overall
Revenue (2000-2015) 97
17.2 Self Testing Distribution Share (2007-2008)
99
17.3 Self Testing, China, Company Share (2006-2007) 100
18 Overview
of Key Companies in China In Vitro Diagnostics Market 101
18.1 F.
Hoffmann-La Roche Ltd. 101
18.1.1 Company Overview 101
18.1.2 Value
Chain Analysis 102
18.1.2.1 Manufacturing 102
18.1.2.2 Product
Development 102
18.2 Abbott Laboratories 104
18.2.1 Company Overview
104
18.2.2 Value Chain Analysis 105
18.2.2.1 Manufacturing 105
18.2.2.2 Product Development 105
18.2.2.3 Sales and Marketing 107
18.3
Beckman Coulter, Inc. 108
18.3.1 Company Overview 108
18.3.2 Value
Chain Analysis 108
18.3.2.1 Manufacturing 109
18.3.2.2 Product
Development 109
18.3.2.3 Sales and Marketing 109
18.3.3 Beckman
Coulter, Inc. Pipeline Products 110
18.3.3.1 Beckman Coulter, Inc.
Pipeline Products By Equipment Type 110
18.3.3.2 Beckman Coulter, Inc.
Pipeline Products By Development Stage 111
18.3.3.3 Beckman Coulter, Inc.
Pipeline Products By Therapy Area 111
18.3.3.4 Beckman Coulter, Inc.
Pipeline Products By News Summary 112
18.4 Dade Behring Holdings, Inc.
113
18.4.1 Company Overview 113
18.5 Ortho-Clinical Diagnostics Inc.
114
18.5.1 Company Overview 114
18.5.2 Ortho-Clinical Diagnostics Inc.
Pipeline Products 114
18.5.2.1 Ortho-Clinical Diagnostics Inc. Pipeline
Products By Equipment Type 114
18.5.2.2 Ortho-Clinical Diagnostics Inc.
Pipeline Products By Development Stage 114
18.5.2.3 Ortho-Clinical
Diagnostics Inc. Pipeline Products By Therapy Area 115
18.5.2.4
Ortho-Clinical Diagnostics Inc. Pipeline Products By News Summary 115
18.6
bioMerieux S.A. 116
18.6.1 Company Overview 116
18.6.2 Value Chain
Analysis 117
18.6.2.1 Manufacturing 117
18.6.2.2 Product Development
118
18.6.2.3 Sales and Marketing 118
18.7 Siemens Healthcare 120
18.7.1 Company Overview 120
18.7.2 Value Chain Analysis 121
18.7.2.1
Manufacturing 121
18.7.2.2 Product Development 121
18.7.2.3 Sales and
Marketing 122
18.8 Gen-Probe Incorporated 123
18.8.1 Company Overview
123
18.8.2 Value Chain Analysis 124
18.8.2.1 Manufacturing 124
18.8.2.2 Product Development 125
18.8.2.3 Sales and Marketing 125
18.8.3 Gen-Probe Incorporated Pipeline Products 126
18.8.3.1 Gen-Probe
Incorporated Pipeline Products By Equipment Type 126
18.8.3.2 Gen-Probe
Incorporated Pipeline Products By Development Stage 126
18.8.3.3 Gen-Probe
Incorporated Pipeline Products By Therapy Area 127
18.8.3.4 Gen-Probe
Incorporated Pipeline Products By Clinical Trials 127
18.8.3.5 Gen-Probe
Incorporated Pipeline Products By News Summary 127
18.9 Becton, Dickinson
and 128
18.9.1 Company Overview 128
18.9.2 Value Chain Analysis
129
18.9.2.1 Manufacturing 129
18.9.2.2 Product Development 129
18.9.2.3 Sales and Marketing 130
18.10 OLYMPUS CORPORATION 131
18.10.1
Company Overview 131
18.10.2 Value Chain Analysis 132
18.10.2.1
Manufacturing 132
18.10.2.2 Product Development 132
18.10.2.3 Sales
and Marketing 133
18.10.3 Olympus Medical Systems Corp. Pipeline Products
133
18.10.3.1 Olympus Medical Systems Corp. Pipeline Products by Equipment
Type 133
18.10.3.2 Olympus Medical Systems Corp. Pipeline Products by
Development Stage 134
18.10.3.3 Olympus Medical Systems Corp. Pipeline
Products by Therapy Area 134
18.10.3.4 Olympus Medical Systems Corp.
Pipeline Products by Clinical Trials 134
18.10.3.5 Olympus Medical Systems
Corp. Pipeline Products by News Summary 134
18.11 Beijing Bio-Ekon
Biotechnology Co., Ltd. 135
18.11.1 Company Overview 135
18.12 Beijing
Pason Pharmaceuticals Inc. 135
18.12.1 Company Overview 135
18.13
Jingmei Biotech Co., Ltd. 135
18.13.1 Company Overview 135
18.14
Mindray Medical International Limited 136
18.14.1 Company Overview 136
18.15 Shanghai Fosun Medical Technology Development Co., Ltd. 136
18.15.1
Company Overview 136
19 Financial Deals Landscape 137
19.1 Merger
137
19.1.1 Pacgen Biopharmaceuticals Terminates Merger Agreement with
Medigen Biotechnology 137
19.2 Acquisition 138
19.2.1 FUJIFILM
Acquires Perseus Proteomics 138
19.3 Partnerships 139
19.3.1
Progentech Enters Into Partnership with China CDC 139
19.3.2 Luminex Signs
an Agreement with Mingyuan Medicare 140
20 Recent Developments 141
20.1 Strategy and Business Planning 141
20.1.1 Jan 16, 2009: Mindray Plans
to Launch Seven to Nine New Products In 2009 141
20.1.2 Feb 28, 2008:
Inverness Medical Plans To Close Unipath Facility 141
20.1.3 Nov 05, 2007:
Adaltis Signs Important Cooperation Agreement with CMDA 141
20.2
Government and Public Interest 142
20.2.1 Apr 01, 2009: Chinese Government
and Foundation Announce Partnership to Fight TB 142
20.2.2 Mar 18, 2009:
MOH: New Rules to Govern High-Risk and Controversial Medical Technologies
143
20.3 Product News 144
20.3.1 Mar 25, 2009: China Medical
Technologies Receives Receipt Of SFDA Quality Testing Certificate For Its SPR
System 144
20.3.2 Mar 06, 2009: QIAGEN Supports Cervical Cancer Screening
For Underprivileged Chinese Women 144
20.3.3 Feb 11, 2009: Zila Announces
the Completion Of First Phase Global Rollout Of ViziLite Plus 144
20.3.4
Jan 22, 2009: China Medical Technologies Receives SFDA Approval for Cervical
Cancer FISH Probe and Prenatal FISH Probe 145
20.3.5 Dec 01, 2008:
Next-Generation Noninvasive Diagnostic Technology Shown to Accurately Detect
Fetal down syndrome in First Trimester of Pregnancy 145
20.3.6 Nov 12,
2008: China Medical Technologies Receives SFDA Approval For Breast Cancer
HER-2 FISH Probe 146
20.3.7 Jul 17, 2008: Mindray to Introduce BC-5380
Hematology Analyzer at AACC 2008 146
21 Appendix 147
21.1 Global
Markets Direct Research Methodology 147
21.2 Coverage 148
21.3
Secondary Research 148
21.4 Primary Research 149
21.5 Models 149
21.6 Forecasts 150
21.7 Expert Panel Validation 150
21.8 Currency
Conversion 151
21.9 Contact Us 152
21.10 Disclaimer 152
1.1
List of Tables
Table 1: Doctors by Specialty in China, 2003-2007 25
Table 2: Hospital Wards by Specialty in China, 2003 - 2007 26
Table 3:
Healthcare Institutions in China, 2000-2006 27
Table 4: Personnel Employed
in Healthcare Institutions in China, 2000-2006 27
Table 5: Healthcare
Institutions, Hospital Beds and Employed Personnel by Region in China, 2006
28
Table 6: In Vitro Diagnostics Cross Country Comparison, Revenue ($
mn), 2000-2015 39
Table 7: In Vitro Diagnostics, China, Overall
Revenue ($ mn), 2000-2015 40
Table 8: In Vitro Diagnostics, China,
Cross-Category Analysis, 2000-2015 41
Table 9: In Vitro Diagnostics,
China, Overall Revenue ($ mn), Historic, 2000-2008 43
Table 10: In
Vitro Diagnostics, China, Overall Revenue ($ mn), Forecast, 2008-2015 45
Table 11: In Vitro Diagnostics, China, Company Share by Revenue ($ mn),
2006-2007 46
Table 12: Blood Test Reagents, China, Revenue ($ mn) by
Segment, Historic, 2000-2008 48
Table 13: Blood Test Reagents, China,
Revenue ($ mn) by Segment, Forecast, 2008-2015 50
Table 14:
Haematology Test Reagents, China, Revenue ($ mn) by Sub-Segment, Historic,
2000-2008 51
Table 15: Haematology Test Reagents, China, Revenue ($
mn) by Sub-Segment, Forecast, 2008-2015 52
Table 16: Hemostasis Test
Reagents, China, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 53
Table 17: Hemostasis Test Reagents, China, Revenue ($ mn) by Sub-Segment,
Forecast, 2008-2015 54
Table 18: Blood Test Reagents, China,
Distribution Share by Revenue ($mn), 2007-2008 55
Table 19: Blood
Test Reagents, China, Company Share by Revenue ($ mn), 2006-2007 56
Table
20: Clinical Chemistry Test Reagents, China, Revenue ($ mn) by Segment,
Historic, 2000-2008 57
Table 21: Clinical Chemistry Test Reagents,
China, Revenue ($ mn) by Segment, Forecast, 2008-2015 58
Table 22:
Clinical Chemistry Test Reagents, China, Distribution Share by Revenue ($mn),
2007-2008 59
Table 23: Clinical Chemistry Test Reagents, China,
Company Share by Revenue ($ mn), 2006-2007 60
Table 24: Genetic Test
Reagents, China, Revenue ($ mn), Historic, 2000-2008 61
Table 25:
Genetic Test Reagents, China, Revenue ($ mn), Forecast, 2008-2015 62
Table
26: Genetic Test Reagents, China, Distribution Share by Revenue ($mn),
2007-2008 63
Table 27: Genetic Test Reagents, China, Company Share by
Revenue ($ mn), 2006-2007 64
Table 28: Immunochemistry Test Reagents,
China, Revenue ($ mn) by Segment, Historic, 2000-2008 66
Table 29:
Immunochemistry Test Reagents, China, Revenue ($ mn) by Segment, Forecast,
2008-2015 68
Table 30: Disease Specific Markers, China, Revenue ($
mn) by Sub-Segment, Historic, 2000-2008 69
Table 31: Disease Specific
Markers, China, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 70
Table 32: Disease Specific Test Reagents, China, Revenue ($ mn) by
Sub-Segment, Historic, 2000-2008 71
Table 33: Disease Specific Test
Reagents, China, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 72
Table 34: Drug Related Testing Reagents, China, Revenue ($ mn) by
Sub-Segment, Historic, 2000-2008 73
Table 35: Drug Related Testing
Reagents, China, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 74
Table 36: Hormone Related Testing Reagents, China, Revenue ($ mn) by
Sub-Segment, Historic, 2000-2008 75
Table 37: Hormone Related Testing
Reagents, China, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 76
Table 38: Immunochemistry Test Reagents, China, Distribution Share by
Revenue ($mn), 2007-2008 77
Table 39: Immunochemistry Test Reagents,
China, Company Share by Revenue ($ mn), 2006-2007 78
Table 40:
Infectious Immunology Test Reagents, China, Revenue ($ mn) by Segment,
Historic, 2000-2008 80
Table 41: Infectious Immunology Test Reagents,
China, Revenue ($ mn) by Segment, Forecast, 2008-2015 82
Table 42:
Virology, China, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 83
Table 43: Virology, China, Revenue ($ mn) by Sub-Segment, Forecast,
2008-2015 84
Table 44: Infectious Immunology Test Reagents, China,
Distribution Share by Revenue ($mn), 2007-2008 85
Table 45:
Infectious Immunology Test Reagents, China, Company Share by Revenue ($ mn),
2006-2007 86
Table 46: Instruments, China, Revenue ($ mn), Historic,
2000-2008 87
Table 47: Instruments, China, Revenue ($ mn), Forecast,
2008-2015 88
Table 48: Instruments, China, Distribution Share by
Revenue ($mn), 2007-2008 89
Table 49: Instruments, China, Company
Share by Revenue ($ mn), 2006-2007 90
Table 50: Microbiology Test
Reagents, China, Revenue ($ mn) by Segment, Historic, 2000-2008 91
Table
51: Microbiology Test Reagents, China, Revenue ($ mn) by Segment,
Forecast, 2008-2015 92
Table 52: Bacteriology Test Reagents, China,
Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 93
Table 53:
Bacteriology Test Reagents, China, Revenue ($ mn) by Sub-Segment, Forecast,
2008-2015 94
Table 54: Microbiology Test Reagents, China,
Distribution Share by Revenue ($mn), 2007-2008 95
Table 55:
Microbiology Test Reagents, China, Company Share by Revenue ($ mn), 2006-2007
96
Table 56: Self Testing, China, Revenue ($ mn), Historic, 2000-2008
97
Table 57: Self Testing, China, Revenue ($ mn), Forecast, 2008-2015
98
Table 58: Self Testing, China, Distribution Share by Revenue
($mn), 2007-2008 99
Table 59: Self Testing, China, Company Share by
Revenue ($ mn), 2006-2007 100
Table 60: Beckman Coulter, Inc.
Pipeline Products by Equipment Type 110
Table 61: Beckman Coulter,
Inc. Pipeline Products By Development Stage 111
Table 62: Beckman
Coulter, Inc. Pipeline Products By Therapy Area 111
Table 63: Beckman
Coulter, Inc. Pipeline Products By News Summary 112
Table 64:
Ortho-Clinical Diagnostics Inc. Pipeline Products by Equipment Type 114
Table 65: Ortho-Clinical Diagnostics Inc. Pipeline Products By
Development Stage 114
Table 66: Ortho-Clinical Diagnostics Inc.
Pipeline Products By Therapy Area 115
Table 67: Ortho-Clinical
Diagnostics Inc. Pipeline Products By News Summary 115
Table 68:
Gen-Probe Incorporated Pipeline Products by Equipment Type 126
Table 69:
Gen-Probe Incorporated Pipeline Products By Development Stage 126
Table
70: Gen-Probe Incorporated Pipeline Products By Therapy Area 127
Table 71: Gen-Probe Incorporated Pipeline Products By Clinical Trials
127
Table 72: Gen-Probe Incorporated Pipeline Products By News
Summary 127
Table 73: Olympus Medical Systems Corp. Pipeline Products
by Equipment Type 133
Table 74: Olympus Medical Systems Corp.
Pipeline Products by Development Stage 134
Table 75: Olympus Medical
Systems Corp. Pipeline Products by Therapy Area 134
Table 76: Olympus
Medical Systems Corp. Pipeline Products by Clinical Trials 134
Table 77:
Olympus Medical Systems Corp. Pipeline Products by News Summary 134
Table 78: Pacgen Biopharmaceuticals Terminates Merger Agreement With
Medigen Biotechnology 137
Table 79: FUJIFILM Acquires Perseus
Proteomics 138
Table 80: Progentech Enters Into Partnership With
China CDC 139
Table 81: Luminex Signs An Agreement With Mingyuan
Medicare 140
Table 82: USD to Local Currency, Average Exchange Rate 2008
151
1.2 List of Figures
Figure 1: Total Healthcare Expenditure in
China, 2000 - 2005 24
Figure 2: Medical Equipment Registration Process in
China, 2007 32
Figure 3: CCC Mark Certification Process in China, 2007
34
Figure 4: In Vitro Diagnostics Cross Country Comparison, Revenue
($ mn), 2000-2015 39
Figure 5: In Vitro Diagnostics, China, Overall
Revenue ($ mn), 2000-2015 40
Figure 6: In Vitro Diagnostics, China,
Cross-Category Analysis, 2000-2015 41
Figure 7: In Vitro Diagnostics,
China, Overall Revenue ($ mn), Historic, 2000-2008 42
Figure 8: In
Vitro Diagnostics, China, Overall Revenue ($ mn), Forecast, 2008-2015 44
Figure 9: In Vitro Diagnostics, China, Company Share (%), 2007 46
Figure 10: Blood Test Reagents, China, Revenue ($ mn) by Segment,
Historic, 2000-2008 47
Figure 11: Blood Test Reagents, China, Revenue
($ mn) by Segment, Forecast, 2008-2015 49
Figure 12: Haematology Test
Reagents, China, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 51
Figure 13: Haematology Test Reagents, China, Revenue ($ mn) by
Sub-Segment, Forecast, 2008-2015 52
Figure 14: Hemostasis Test
Reagents, China, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 53
Figure 15: Hemostasis Test Reagents, China, Revenue ($ mn) by
Sub-Segment, Forecast, 2008-2015 54
Figure 16: Blood Test Reagents,
China, Company Share (%), 2007 56
Figure 17: Clinical Chemistry Test
Reagents, China, Revenue ($ mn) by Segment, Historic, 2000-2008 57
Figure
18: Clinical Chemistry Test Reagents, China, Revenue ($ mn) by Segment,
Forecast, 2008-2015 58
Figure 19: Clinical Chemistry Test Reagents,
China, Company Share (%), 2007 60
Figure 20: Genetic Test Reagents,
China, Revenue ($ mn), Historic, 2000-2008 61
Figure 21: Genetic Test
Reagents, China, Revenue ($ mn), Forecast, 2008-2015 62
Figure 22:
Genetic Test Reagents, China, Company Share (%), 2007 64
Figure 23:
Immunochemistry Test Reagents, China, Revenue ($ mn) by Segment, Historic,
2000-2008 65
Figure 24: Immunochemistry Test Reagents, China, Revenue
($ mn) by Segment, Forecast, 2008-2015 67
Figure 25: Disease Specific
Markers, China, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 69
Figure 26: Disease Specific Markers, China, Revenue ($ mn) by
Sub-Segment, Forecast, 2008-2015 70
Figure 27: Disease Specific Test
Reagents, China, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 71
Figure 28: Disease Specific Test Reagents, China, Revenue ($ mn) by
Sub-Segment, Forecast, 2008-2015 72
Figure 29: Drug Related Testing
Reagents, China, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 73
Figure 30: Drug Related Testing Reagents, China, Revenue ($ mn) by
Sub-Segment, Forecast, 2008-2015 74
Figure 31: Hormone Related
Testing Reagents, China, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
75
Figure 32: Hormone Related Testing Reagents, China, Revenue ($ mn)
by Sub-Segment, Forecast, 2008-2015 76
Figure 33: Immunochemistry
Test Reagents, China, Company Share (%), 2007 78
Figure 34:
Infectious Immunology Test Reagents, China, Revenue ($ mn) by Segment,
Historic, 2000-2008 79
Figure 35: Infectious Immunology Test
Reagents, China, Revenue ($ mn) by Segment, Forecast, 2008-2015 81
Figure
36: Virology, China, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
83
Figure 37: Virology, China, Revenue ($ mn) by Sub-Segment,
Forecast, 2008-2015 84
Figure 38: Infectious Immunology Test
Reagents, China, Company Share (%), 2007 86
Figure 39: Instruments,
China, Revenue ($ mn), Historic, 2000-2008 87
Figure 40: Instruments,
China, Revenue ($ mn), Forecast, 2008-2015 88
Figure 41: Instruments,
China, Company Share (%), 2007 90
Figure 42: Microbiology Test
Reagents, China, Revenue ($ mn) by Segment, Historic, 2000-2008 91
Figure
43: Microbiology Test Reagents, China, Revenue ($ mn) by Segment,
Forecast, 2008-2015 92
Figure 44: Bacteriology Test Reagents, China,
Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 93
Figure 45:
Bacteriology Test Reagents, China, Revenue ($ mn) by Sub-Segment, Forecast,
2008-2015 94
Figure 46: Microbiology Test Reagents, China, Company
Share (%), 2007 96
Figure 47: Self Testing, China, Revenue ($ mn),
Historic, 2000-2008 97
Figure 48: Self Testing, China, Revenue ($
mn), Forecast, 2008-2015 98
Figure 49: Self Testing, China, Company
Share (%), 2007 100
Figure 50: F. Hoffmann-La Roche Ltd Value Chain
Analysis 102
Figure 51: Abbott Laboratories Value Chain Analysis
105
Figure 52: Beckman Coulter, Inc. Value Chain Analysis 108
Figure 53: Biomerieux Sa Value Chain Analysis 117
Figure 54:
Siemens Medical Solutions Value Chain Analysis 121
Figure 55:
Gen-Probe Incorporated Value Chain Analysis 124
Figure 56: Becton,
Dickinson and Company Value Chain Analysis 129
Figure 57: Olympus
Medical Systems Corp. Value Chain Analysis 132
Figure 58: Global
Markets Direct Methodology 147
|
Related Report
|
View Cart
